# Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

> **NCT01348503** · PHASE1 · TERMINATED · sponsor: **Indiana University** · enrollment: 5 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01348503
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-12
- **Final completion:** 2014-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Treatment was ineffective
- **Last updated:** 2015-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348503, "Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT01348503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*